Share on LinkedInShare on LinkedIn

ARTICLE · 29 AUGUST 2017

Jury Tests the Limits in AndroGel False Ad Verdict

Proskauer Rose LLP
Proskauer Rose LLP
Contributor
Proskauer Rose LLP

Proskauer Rose LLP

Firm Overview Proskauer is an elite global law firm with more than 900 lawyers across key financial...

View firm profile
Explore more from Proskauer Rose LLP

In late July, an Illinois jury came to a bizarre verdict in a case over an alleged link between heart attacks and AndroGel, a gel product used for treating low testosterone (or "low T").

United StatesMedia, Telecoms, IT, Entertainment

In late July, an Illinois jury came to a bizarre verdict in a case over an alleged link between heart attacks and AndroGel, a gel product used for treating low testosterone (or "low T"). The jury found that AbbVie, Inc., the drug company behind AndroGel, although not strictly liable or negligent in allegedly causing a user's heart attack and owing $0 in compensatory damages, was nevertheless liable for fraudulent misrepresentation in its product advertising and was responsible for $150 million in punitive damages.

Over the past few years, roughly 6,000 individuals have filed lawsuits linked to testosterone gel products alleging health concerns, like heart attacks.  One of those lawsuits was brought by Jesse Mitchell in Illinois district court in 2014.  This July, Mitchell's lawsuit became the first of these cases to reach a jury verdict, and could have an important impact on the vitality of the remaining lawsuits.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from